Phase 2
Lung Transplant
Intervention Type:
Intravenous (IV) Injection
Funder Type:
Organization | University

Drug Details

Carfilzomib is in a class of medications called proteasome inhibitors. 

Study Purpose

The clinical trial is a Phase II open label, single-arm pilot study to evaluate the safety and efficacy of combination therapy with carfilzomib, plasma exchange and intravenous immunoglobulins for AMR after lung transplantation and elucidate important clinical and immunologic phenotypes and mechanisms associated with these outcomes.

Find a Clinical Trial